Cargando…
Effectiveness and Safety of Mitral Valve Plasty in Patients with an Anomalous Origin of the Coronary Artery from the Pulmonary Artery
The study aimed to determine the effectiveness and safety of anomalous coronary artery from pulmonary artery (ACAPA) patients with moderate or severe mitral valve regurgitation (MVR) receiving mitral valve plasty (MVP) concurrently. Consecutive ACAPA patients undergoing surgery between 2015 and 2021...
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9959487/ https://www.ncbi.nlm.nih.gov/pubmed/36826571 http://dx.doi.org/10.3390/jcdd10020075 |
_version_ | 1784895288813551616 |
---|---|
author | Lv, Lizhi Lang, Xinyue Zhang, Simeng Wang, Cheng Jin, Yuanhao Zhi, Aihua Wang, Qiang |
author_facet | Lv, Lizhi Lang, Xinyue Zhang, Simeng Wang, Cheng Jin, Yuanhao Zhi, Aihua Wang, Qiang |
author_sort | Lv, Lizhi |
collection | PubMed |
description | The study aimed to determine the effectiveness and safety of anomalous coronary artery from pulmonary artery (ACAPA) patients with moderate or severe mitral valve regurgitation (MVR) receiving mitral valve plasty (MVP) concurrently. Consecutive ACAPA patients undergoing surgery between 2015 and 2021 were retrospectively included. Patients were divided into three groups: moderate MVR without MVP (non-MVP (moderate) N = 14), moderate MVR with MVP (MVP (moderate) N = 13), and severe MVR with MVP (MVP (severe) N = 13). The primary safety endpoint was in-hospital surgery-related complications. The primary effectiveness outcome was left ventricular ejection function (LVEF) and left ventricular end-diastolic diameter (LVEDD) z-score at 2- and 24-month follow-ups. Multivariable linear regression models were used to obtain the β coefficient. The median age of the included patients was 7.5 years (IQR 1.4–26.5). The in-hospital surgery-related complication rates were 7.1%, 15.4%, and 7.7% in non-MVP (moderate), MVP (moderate), and MVP (severe) groups, separately. At the 2-month follow-up, the non-MVP (moderate) group had a better LVEF and LVEDD z-score compared with the MVP (moderate) group (LVEF β = 9.22, 95%CI 1.09 to 17.35; LVEDD z-score β = −2.49, 95%CI −4.53 to −0.45). At the 24-month follow-up, the LVEF of all patients and the LVEDD z-score of 90% of patients in the three groups returned to normal. For ACAPA patients with moderate MVR, MVP was not necessary, especially for pediatric patients (age < 3 years) and patients with secondary MVR. Further studies for ACAPA patients with severe MVR are still needed. |
format | Online Article Text |
id | pubmed-9959487 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-99594872023-02-26 Effectiveness and Safety of Mitral Valve Plasty in Patients with an Anomalous Origin of the Coronary Artery from the Pulmonary Artery Lv, Lizhi Lang, Xinyue Zhang, Simeng Wang, Cheng Jin, Yuanhao Zhi, Aihua Wang, Qiang J Cardiovasc Dev Dis Article The study aimed to determine the effectiveness and safety of anomalous coronary artery from pulmonary artery (ACAPA) patients with moderate or severe mitral valve regurgitation (MVR) receiving mitral valve plasty (MVP) concurrently. Consecutive ACAPA patients undergoing surgery between 2015 and 2021 were retrospectively included. Patients were divided into three groups: moderate MVR without MVP (non-MVP (moderate) N = 14), moderate MVR with MVP (MVP (moderate) N = 13), and severe MVR with MVP (MVP (severe) N = 13). The primary safety endpoint was in-hospital surgery-related complications. The primary effectiveness outcome was left ventricular ejection function (LVEF) and left ventricular end-diastolic diameter (LVEDD) z-score at 2- and 24-month follow-ups. Multivariable linear regression models were used to obtain the β coefficient. The median age of the included patients was 7.5 years (IQR 1.4–26.5). The in-hospital surgery-related complication rates were 7.1%, 15.4%, and 7.7% in non-MVP (moderate), MVP (moderate), and MVP (severe) groups, separately. At the 2-month follow-up, the non-MVP (moderate) group had a better LVEF and LVEDD z-score compared with the MVP (moderate) group (LVEF β = 9.22, 95%CI 1.09 to 17.35; LVEDD z-score β = −2.49, 95%CI −4.53 to −0.45). At the 24-month follow-up, the LVEF of all patients and the LVEDD z-score of 90% of patients in the three groups returned to normal. For ACAPA patients with moderate MVR, MVP was not necessary, especially for pediatric patients (age < 3 years) and patients with secondary MVR. Further studies for ACAPA patients with severe MVR are still needed. MDPI 2023-02-09 /pmc/articles/PMC9959487/ /pubmed/36826571 http://dx.doi.org/10.3390/jcdd10020075 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Lv, Lizhi Lang, Xinyue Zhang, Simeng Wang, Cheng Jin, Yuanhao Zhi, Aihua Wang, Qiang Effectiveness and Safety of Mitral Valve Plasty in Patients with an Anomalous Origin of the Coronary Artery from the Pulmonary Artery |
title | Effectiveness and Safety of Mitral Valve Plasty in Patients with an Anomalous Origin of the Coronary Artery from the Pulmonary Artery |
title_full | Effectiveness and Safety of Mitral Valve Plasty in Patients with an Anomalous Origin of the Coronary Artery from the Pulmonary Artery |
title_fullStr | Effectiveness and Safety of Mitral Valve Plasty in Patients with an Anomalous Origin of the Coronary Artery from the Pulmonary Artery |
title_full_unstemmed | Effectiveness and Safety of Mitral Valve Plasty in Patients with an Anomalous Origin of the Coronary Artery from the Pulmonary Artery |
title_short | Effectiveness and Safety of Mitral Valve Plasty in Patients with an Anomalous Origin of the Coronary Artery from the Pulmonary Artery |
title_sort | effectiveness and safety of mitral valve plasty in patients with an anomalous origin of the coronary artery from the pulmonary artery |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9959487/ https://www.ncbi.nlm.nih.gov/pubmed/36826571 http://dx.doi.org/10.3390/jcdd10020075 |
work_keys_str_mv | AT lvlizhi effectivenessandsafetyofmitralvalveplastyinpatientswithananomalousoriginofthecoronaryarteryfromthepulmonaryartery AT langxinyue effectivenessandsafetyofmitralvalveplastyinpatientswithananomalousoriginofthecoronaryarteryfromthepulmonaryartery AT zhangsimeng effectivenessandsafetyofmitralvalveplastyinpatientswithananomalousoriginofthecoronaryarteryfromthepulmonaryartery AT wangcheng effectivenessandsafetyofmitralvalveplastyinpatientswithananomalousoriginofthecoronaryarteryfromthepulmonaryartery AT jinyuanhao effectivenessandsafetyofmitralvalveplastyinpatientswithananomalousoriginofthecoronaryarteryfromthepulmonaryartery AT zhiaihua effectivenessandsafetyofmitralvalveplastyinpatientswithananomalousoriginofthecoronaryarteryfromthepulmonaryartery AT wangqiang effectivenessandsafetyofmitralvalveplastyinpatientswithananomalousoriginofthecoronaryarteryfromthepulmonaryartery |